GlycoEra has expanded Series A financing with an investment from the global pharmaceutical group Bristol Myers Squibb
scroll south
GlycoEra, the Swiss startup advancing a pipeline of extracellular protein degraders for the treatment of autoimmune disorders has secured fresh funding from Bristol Myers Squibb as part of its Series A extension.
Intending to advance innovative therapies, biotech GlycoEra has announced an expansion of its Series A financing, fortified by a strategic investment from global pharmaceutical giant Bristol Myers Squibb. Headquartered in Massachusetts and the canton of Zurich, GlycoEra is dedicated to pushing the boundaries of therapeutic possibilities by developing brand-new treatments aimed at dismantling pathogenic proteins. This investment not only pushes GlycoEra's mission forward but also underscores the pharmaceutical industry's recognition of the company's potential to impact the field of biotechnology.Bristol Myers Squibb joins existing investors, including 5AM Ventures, Roche Venture Fund, and Sofinnova Partners, to advance GlycoEra's preclinical programs. The company's pipeline includes innovative drugs to treat a range of autoimmune diseases through the rapid and profound degradation of pathogenic proteins. These can be relevant in a variety of application areas such as oncology, neurology and infectious diseases.
Additionally, GlycoEra welcomed industry veteran Dr. Recruit Greg Fralish as Chief Business Officer. He brings more than 20 years of experience in a variety of roles in business development and strategy, spanning both large pharma and biotech.
GlycoEra was ranked among the TOP 100 Swiss Startups in 2022 and 2023.
GlycoEra's team: CBO Greg Fralish, CSO Tanmoy C. Ganguly, and CEO Ganesh V. Kaundinya
